NITO N2OFF Inc.

Subscribe to $NITO

N2OFF Inc.

Subscribe to $NITO

$NITO

Agricultural Chemicals

Industrials

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for N2OFF Inc.

Date	Price Target	Rating	Analyst

See more ratings

N2OFF Inc. Press Releases

Fastest customizable press release news feed in the world

View All

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

Neve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced the closing of the merger with MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's pr

10/30/25 9:25:00 AM ET

$NITO

$SPRC

Agricultural Chemicals

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the closing of the sale to N2OFF, Inc. (NASDAQ:NITO) ("N2OFF") of SciSparc's majority owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"). MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's proprietary algorithm that enables reliable 3D comparative modeling of mitochon

10/23/25 4:03:00 PM ET

$NITO

$SPRC

Agricultural Chemicals

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Neve Yarak, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today the closing of the merger with MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's propr

10/23/25 8:25:00 AM ET

$NITO

$SPRC

Agricultural Chemicals

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement

Neve Yarak, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq"), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company had previously announced on March 28, 2025, that it was notified by Nasdaq that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the clos

10/8/25 9:00:00 AM ET

$NITO

Agricultural Chemicals

Industrials

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that on September 25, 2025, the stockholders of N2OFF, Inc. (NASDAQ: NITO) ("N2OFF") voted on and approved, among other things, the proposed acquisition of SciSparc's majority owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"). This important milestone, achieved at N2OFF's special meeting of stockholders held on September 25, 2025, clears a key path for the completion of the Acquisition, which would result in MitoCareX beco

9/29/25 4:03:00 PM ET

$NITO

$SPRC

Agricultural Chemicals

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today that a special meeting of stockholders held on September 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by target

9/25/25 4:01:00 PM ET

$NITO

$SPRC

Agricultural Chemicals

Industrials

Biotechnology: Pharmaceutical Preparations

Health Care

N2OFF Announces Reverse Stock Split

Neve Yarak, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.\ (NASDAQ:NITO) (FSE:80W) ("N2OFF" or the "Company"), a clean tech company engaged in sustainable solutions for the energy and agri-tech industries, announced that its Board of Directors has approved a one-for-thirty-five (1-for-35) reverse stock split of its common stock that is scheduled to become effective for Nasdaq purposes on September 22, 2025. Beginning on September 22, 2025, the Company's common stock will trade on the Nasdaq Capital Market on a split adjusted basis under a new CUSIP number 80512Q501. The Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "NITO." As previousl

9/18/25 9:00:00 AM ET

$NITO

Agricultural Chemicals

Industrials

N2OFF Provides Business Update on Successful Execution of Solar and Energy Storage Initiatives Across Europe

Neve Yarak, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced significant progress in its solar and energy storage initiatives, highlighting the successful execution of key projects in Germany, Italy, and Poland. Through its strategic partnership with Solterra Renewable Energy Ltd. ("Solterra"), N2OFF is advancing a robust portfolio of renewable energy projects, reinforcing its commitment to driving the global clean energy transition. Key Solar and Energy Storage Projects Melz Solar PV Project – Germany (111 MWp) Descrip

9/18/25 7:50:00 AM ET

$NITO

Agricultural Chemicals

Industrials

N2OFF to Expand its Melz Solar Project with Battery Storage

According to Entrix, the project's expansion is projected to boost the project's revenue, potentially paving the way for higher returns to N2OFF's stockholders. Neve Yarak, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, today announced its decision to extend additional debt financing to Solterra Renewable Energy Ltd. ("Solterra") in connection with its previously reported Melz solar project for the purpose of integrating a large-scale battery energy storage system (BESS) into its 115 MWp solar photovoltaic project in Melz, Germany. The p

9/11/25 7:42:00 AM ET

$NITO

Agricultural Chemicals

Industrials

N2OFF Completes $1.2 million of its $2.7 million Total Commitment to Finance 196MWp Battery Energy Storage Assets in Italy

According to industry sources, "Ready to Build" battery storage projects of this capacity may yield up to $13.5 million Neve Yarak, Israel, July 11, 2025 (GLOBE NEWSWIRE) -- Today, N2OFF, Inc.(NASDAQ:NITO) (FSE:80W) ("N2OFF" and the "Company"), a cleantech company investing in "Agrifood" Techs Solutions and sustainable energy solutions through Solar Energy assets based on the RTB (Ready to Build ) business model, announced completion of the second installment of a $2.7 million investment for financing and supporting the development of two Battery Energy Storage Systems ("BESS") in Sicily, Italy, each with a capacity of 98MWp/392MWh. To date, the Company has invested over $1.2 million in

7/11/25 8:40:00 AM ET

$NITO

Agricultural Chemicals

Industrials

N2OFF Inc.

Recent Analyst Ratings for N2OFF Inc.

N2OFF Inc.

Recent Analyst Ratings for N2OFF Inc.

N2OFF Inc. Insider Purchases

Director Rosenbloom Ronen bought 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

N2OFF Inc. Press Releases

N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

N2OFF Regains Compliance with Nasdaq Minimum Bid Price Requirement

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

N2OFF Announces Reverse Stock Split

N2OFF Provides Business Update on Successful Execution of Solar and Energy Storage Initiatives Across Europe

N2OFF to Expand its Melz Solar Project with Battery Storage

N2OFF Completes $1.2 million of its $2.7 million Total Commitment to Finance 196MWp Battery Energy Storage Assets in Italy

N2OFF Inc. SEC Filings

SEC Form DEF 14A filed by N2OFF Inc.

SEC Form SCHEDULE 13G filed by N2OFF Inc.

SEC Form PRE 14A filed by N2OFF Inc.

N2OFF Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

N2OFF Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

N2OFF Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

N2OFF Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

N2OFF Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

SEC Form 424B3 filed by N2OFF Inc.

SEC Form EFFECT filed by N2OFF Inc.

N2OFF Inc. Insider Trading

New insider Silberman Alon claimed ownership of 454,127 shares (SEC Form 3)

New insider Scisparc Ltd. claimed ownership of 490,751 shares (SEC Form 3)

Chief Financial Officer Barda Lital was granted 300,000 units of Restricted Shares of Common Stock (SEC Form 4)

Chief Executive Officer Palach David was granted 600,000 units of Restricted Shares of Common Stock (SEC Form 4)

Director Sidi Liat was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)

Director Arbib Eliahou was granted 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

Director Berenstein Israel Yakov was granted 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

Director Kalifi Udi Ovadia was granted 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 271% to 68,457 units (SEC Form 4)

Director Itzhaik Asaf was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)

Director Weiss Amitay was granted 350,000 units of Restricted Shares of Common Stock, increasing direct ownership by 350% to 450,000 units (SEC Form 4)

N2OFF Inc. Financials

N2OFF Announces Strategic Initiatives Intended to Maximize Shareholder Value